{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:34:17Z","timestamp":1783578857031,"version":"3.55.0"},"reference-count":0,"publisher":"Termedia Sp. z.o.o.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Med Sci"],"published-print":{"date-parts":[[2024,1,31]]},"abstract":"<jats:p>Lipid disorders, primarily hypercholesterolemia, are the most common cardiovascular (CV) risk factor in Poland (this applies even 3\/4 of people). The low-density lipoprotein cholesterol (LDL-C) serum level is the basic lipid parameter that should be measured to determine CV risk and determines the aim and target of lipid-lowering treatment (LLT). Lipid-lowering treatment improves cardiovascular prognosis and prolongs life in both primary and secondary cardiovascular prevention. Despite the availability of effective lipid-lowering drugs and solid data on their beneficial effects, the level of LDL-C control is highly insufficient. This is related, among other things, to physician inertia and patients\u2019 fear of side effects. The development of lipidology has made drugs available with a good safety profile and enabling personalisation of therapy. Pitavastatin, the third most potent lipid-lowering statin, is characterised by a lower risk of muscle complications and new cases of diabetes due to its being metabolised differently. Thus, pitavastatin is a very good therapeutic option in patients at high risk of diabetes or with existing diabetes, and in patients at cardiovascular risk. This expert opinion paper attempts at recommendation on the place and possibility of using pitavastatin in the treatment of lipid disorders.<\/jats:p>","DOI":"10.5114\/aoms\/175879","type":"journal-article","created":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T00:53:47Z","timestamp":1700960027000},"page":"28-42","source":"Crossref","is-referenced-by-count":9,"title":["Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association"],"prefix":"10.5114","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"first","affiliation":[{"name":"Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland"},{"name":"Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States"},{"name":"Cardiovascular Research Centre, University of Zielona Gora in Zielona Gora, Poland"},{"name":"Department of Cardiology and Adult Congenital Heart Diseases, Polish Mother\u2019s Memorial Hospital Research Institute (PMMHRI), Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8073-6664","authenticated-orcid":false,"given":"Stanis\u0142aw","family":"Surma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2020-3027","authenticated-orcid":false,"given":"Agnieszka","family":"Kap\u0142on-Cie\u015blicka","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9309-674X","authenticated-orcid":false,"given":"Przemys\u0142aw","family":"Mitkowski","sequence":"additional","affiliation":[{"name":"1st Department of Cardiology, Karol Marcinkowski Poznan Medical University, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9742-1797","authenticated-orcid":false,"given":"Grzegorz","family":"Dzida","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Medical University of Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9109-4174","authenticated-orcid":false,"given":"Tomasz","family":"Tomasik","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Collegium Medicum, Jagiellonian University, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6600-2760","authenticated-orcid":false,"given":"Agnieszka","family":"Mastalerz-Migas","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Piast\u00f3w \u015al\u0105ski Medical University, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2023,11,26]]},"container-title":["Archives of Medical Science"],"original-title":[],"link":[{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-175879-104748","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-175879-104748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T07:09:31Z","timestamp":1707894571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.archivesofmedicalscience.com\/Position-paper-of-the-Polish-Expert-Group-on-the-use-of-pitavastatin-in-the-treatment,175879,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,26]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"alternative-id":["175879"],"URL":"https:\/\/doi.org\/10.5114\/aoms\/175879","relation":{},"ISSN":["1734-1922","1896-9151"],"issn-type":[{"value":"1734-1922","type":"print"},{"value":"1896-9151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,26]]}}}